References
- Abbas, M.K., Zaidi, A.R.Z., Robert, C.A., Thiha, S., and Malik, B.H. (2019). The safety of long-term daily usage of a proton pump inhibitor: A literature review.Cureus, 11(9): e5563. https://doi.org/10.7759/cureus.5563
- Afolabi, S.O., Akindele, A.J., Awodele, O., Anunobi, C.C., and Adeyemi, O.O. (2012). A 90 day chronic toxicity study of Nigerian herbal preparation DAS-77 in rats. BMC Complementary and Alternative Medicine, 12: 1-18. DOI: 10.1186/1472-6882-12-79
- Ali, T., Roberts, D.N., and Tierney, W.M. (2009). Long-term safety concerns with proton pump inhibitors. American Journal of Medicine, 10: 896-903. DOI: 10.1016/j.amjmed.2009.04.014
- Al-Sayed, E., and El-Naga, R. N. (2015). Protective role of ellagitannins from Eucalyptus citriodora against ethanol-induced gastric ulcer in rats: impact on oxidative stress, inflammation and calcitonin-gene related peptide. Phytomedicine, 22: 5-15. DOI: 10.1016/j.phymed.2014.10.002
- Amida, M.B., Yemitan, O.K., and Adeyemi, O.O. (2007). Toxicological assessment of the aqueous root extract of Sansevieraliberica Gerome and Labroy (Agavaceae). Journal of Ethnopharmacolo gy, 113(1):171-175. DOI: 10.1016/j.jep.2007.03.033
- Arnold, R., and Koop, H. (1989). Omeprazole: Long-term safety. Digestion, 44: 77-86. DOI: 10.1159/000200107
- Attwood, S.E., Ell, C., Galmiche, J.P., Fiocca, R., Hatlebakk, J.G., Hasselgren, B., Langstrom, G., Jahreskog, M., Eklund, S., Lind, T., and Lundell, L. (2015). Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology and Therapeutics, 41(11): 1162-1174. DOI: 10.1111/apt.13194
- Banihani, S.A. (2016). Omeprazole and semen quality. Basic and Clinical Pharmacology and Toxicology, 118(3): 181-183. DOI: 10.1111/bcpt.12529
- Bate, C.M., Riley, S.A., Chapman, R.W.G., Durnin, A.T., and Taylor, M.D. (1999). Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics,13(1):59-66. DOI: 10.1046/j.1365-2036.1999.00429.x
- Biswas, K., Bandyopadhyay, U., Chattopadhyay, I., Varadaraj, A., Ali, E., and Banerjee, R.K. (2003). A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. Journal of Biological Chemistry, 278(13): 10993-11001. DOI: 10.1074/jbc.M210328200
- Braga, A.L., de Meneses, A.A.P.M., Santos, J.V. de O., dos Reis, A.C., de Lima, R.M.T., da Mata, A.M.O.F., Paz, M.F.C.J., Alves, L.B. dos S., Shaw, S., Uddin, S.J., Rouf, R., Das, A.K., Dev, S., Shil, M.C., Shilpi, J.A., Khan, I.N., Islam, M.T., Ali, E.S., Mubarak, M.S., Mishra, S.K., e Sousa, J.M. de C., and Melo-Cavalcante, A.A. de C. (2018). Toxicogenetic study of omeprazole and the modulatory effects of retinol palmitate and ascorbic acid on Allium cepa. Chemosphere, 204:220-226. DOI: 10.1016/j.chemosphere.2018.04.021
- Braga, A.L., do Nascimento, P.B., Paz, M.F.C.J., de Lima, R.M.T., Santos, J.V. de O., de Alencar, M.V.O.B., de Meneses, A.A.P.M., Júnior, A.L.G., Islam, M.T., Sousa, J.M. de C. e., and Melo-Cavalcante, A.A. de C. (2021). Antioxidative defense against omeprazole-induced toxicogenetical effects in Swiss mice. Pharmacological Reports, 73: 551-562. DOI: 10.1007/s43440-021-00219-1
- Cheesbrough, M. (2005). District laboratory practice in tropical countries, District Laboratory Practice in Tropical Countries. https://doi.org/10.1017/CBO9780511581304
- Chen, W.C., Li, Y. da, Chiang, P.H., Tsay, F.W., Chan, H.H., Tsai, W.L., Tsai, T.J., Wang, E.M., Cheng, J.S., and Lai, K.H. (2014). Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: A retrospective cohort study. BioMed Research International, 2014:693567. https://doi.org/10.1155/2014/693567
- Downes, N., and Foster, J. (2015). Regulatory forum opinion piece: Carcinogen risk assessment: The move from screens to science. Toxicologic Pathology, 43(8):1064-1073. DOI: 10.1177/0192623315598578
- Elmahdy, Marwa F., and Almater, Jadees M. (2019). Omeprazole induced increase in liver markers-A case report. Journal of Clinical & Diagnostic Research, 13(10): 1-2. DOI: 10.7860/JCDR/2019/41848.13218
- Ertenli, I., Kiraz, S., Öztürk, M.A., Haznedaroǧlu, I.C., Çelik, I., and Çalgüneri, M. (2003). Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatology International, 23: 49-60. DOI: 10.1007/s00296-003-0289-0
- Fass, R., Ofman, J.J., Gralnek, I.M., Johnson, C., Camargo, E., Sampliner, R.E., and Fennerty, M.B. (1999). Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Archives of Internal Medicine,159(18): 2161-2168. DOI: 10.1001/archinte.159.18.2161
- Fatima, S., Sheikh, N., and Tayyeb, A. (2019). Investigation of hepatic and renal toxicity induced by omeprazole in CCl4 injury mouse model. Zeitschrift für Gastroenterologie, 57(01): e12. DOI: 10.1055/s-0038-1677070
- Forgacs, I., and Loganayagam, A. (2008). Overprescribing proton pump inhibitors. BMJ,336:2. https://doi.org/10.1136/bmj.39406.449456.BE
- Forgerini, M., Mieli, S., and Mastroianni, P. de C. (2018). Safety assessment of omeprazole use: A review. Sao Paulo Medical Journal, 136(06):557-570.DOI: 10.1590/1516-3180.2018.0019220318
- Ganguly, K., Kundu, P., Banerjee, A., Reiter, R.J, and Swarnakar, S. (2006). Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radical Biology and Medicine, 41: 911-925. DOI: 10.1016/j.freeradbiomed.2006.04.022
- Giannakeas, V., Narod, S.A. (2021). Incidence of cancer among adults with thrombocytosis in Ontario, Canada. JAMA Network Open, 4(8): e2120633. https://doi.org/10.1001/jamanetworkopen.2021.20633
- Guduru, J., and Singh, T.R. (2016). Evaluation of genotoxicity of gastric proton pump inhibitor omeprazole and role of vitamin-E in mice. The Pharma Innovation Journal, 5: 66-71. https://www.thepharmajournal.com/archives/2016/vol5issue8/PartB/5-7-25-804.pdf
- Heidelbaugh, J.J., Kim, A.H., and Walker, P.C. (2012). Overutilization of proton-pump inhibitors: What the clinician needs to know. Therapeutic Advances in Gastroenterology, 5(4): 219-232. DOI: 10.1177/1756283X12437358
- Herbet, M., Izdebska, M., Piątkowska-Chmiel, I., Poleszak, E., and Jagiełło-Wójtowicz, E. (2016). Estimation of oxidative stress parameters in rats after simultaneous administration of rosuvastatin with antidepressants. Pharmacological Reports, 68(1): 172-176. DOI: 10.1016/j.pharep.2015.08.004
- Hess, M.W., Hoenderop, J.G.J., Bindels, R.J.M., and Drenth, J.P.H. (2012). Systematic review: Hypomagnesaemia induced by proton pump inhibition. Alimentary Pharmacology and Therapeutics, 36(5): 405-413. DOI: 10.1111/j.1365-2036.2012.05201.x
- Ishola, I.O., Akindele, A.J., and Adeyemi, O.O. (2012). Sub-chronic toxicity study of the methanol root extract of Cnestisferruginea. Pharmaceutical Biology, 50: 994-1006. DOI: 10.3109/13880209.2012.655376
- Jassim, S.Y., and Nasser, R.A.A. (2018). Effect of omeprazole on liver functions of laboratory rat (albino) Rattus norvegicus. International Journal of Biosciences, 12(6): 123-128. DOI: http://dx.doi.org/10.12692/ijb/12.6.123-128
- Joelson, S., Joelson, I.B., Lundborg, P., Walan, A., and Wallander, M.A. (1992). Safety experience from long-term treatment with omeprazole. Digestion, 51(Suppl 1): 93-101. DOI: 10.1159/000200922
- Kalra, A., Yetisku, E., Wehrle, C.J., and Tuma, F. (2018). Physiology, Liver, StatPearls. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK535438/
- Kiguba, R., Olsson, S., and Waitt, C. (2023). Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa. British Journal of Clinical Pharmacology, 89(2): 491-509. DOI: 10.1111/bcp.15193
- Koch, T.R., Yuan, L.X, Petro, A., and Opara, E.C. (2002). Effects of omeprazole and ascorbate on gastric emptying and antioxidant levels in a mouse model of glutathione depletion. Digestive Diseases and Sciences, 47: 2486-2492. DOI: 10.1023/a:1020555925142
- Kucuk H.F., Akyol H., Kaptanoglu L., Kurt N., Barisik N.O., Bingul S., Torlak O.A., and Colak E. (2006). Effect of proton pump inhibitors on hepatic regeneration. European Surgical Research, 38:322-328. DOI: 10.1159/000094020
- Laheij, R.J.F., Sturkenboom, M.C.J.M., Hassing, R.J., Dieleman, J., Stricker, B.H.C., and Jansen, J.B.M.J. (2004). Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA, 292(16): 1955-1960. DOI: 10.1001/jama.292.16.1955
- Li, W., Zeng, S., Yu, L.S., and Zhou, Q. (2013). Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Therapeutics and Clinical Risk Management, 9: 259-271. DOI: 10.2147/TCRM.S43151
- Lundell, L. (2015). The physiological background behind and course of development of the first proton pump inhibitor. Scandinavian Journal of Gastroenterology, 50(6): 680-684. DOI: 10.3109/00365521.2015.1013981
- Mastroianni, P.D.C., Varallo, F.R., Barg, M.S., Noto, A.R., and Galduroz, J.C.F. (2009). Contribution of the use of drugs for hospital admission. [Portuguese] Contribuicao do uso de medicamentos para aadmissaohospitalar. Brazilian Journal of Pharmaceutical Sciences, 45(1): 163-170. DOI10.1590/s1984-82502009000100020
- Moayyedi, P., and Leontiadis, G.I. (2012). The risks of PPI therapy. Nature Reviews Gastroenterology & Hepatology, 9: 132-139. https://doi.org/10.1038/nrgastro.2011.272
- National Academy of Sciences (2011). Guide for the Care and Use of Laboratory Animals, 8th edition. ed. National Academies Press, Washington DC. doi: 10.17226/12910
- Neumann, H.G. (2009). Risk assessment of chemical carcinogens and thresholds. Critical Reviews in Toxicology, 39(6): 449-461. DOI: 10.1080/10408440902810329
- Ogli, S.A., Enyikwola, O., and Odeh, S.O. (2009). Evaluation of the efficacy of separate oral supplements compared with the combined oral supplements of vitamins C and E on sperm motility in Wistar rats. Nigerian Journal of Physiological Sciences, 24: 129-135. DOI: 10.4314/njps.v24i2.52931
- Olbe, L., Carlsson, E., and Lindberg, P. (2003). A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. Nature Reviews Drug Discovery, 2: 132-139. DOI: 10.1038/nrd1010
- Paz, M.F.C.J., de Alencar, M.V.O.B., de Lima, R.M.I.P., Sobral, A.L.P., do Nascimento, G.T.M., dos Reis, C.A., Coêlho, M.D.P.S.D.S., do Nascimento, M.L.L.B., Gomes Júnior, A.L., MacHado, K.D.C., de Menezes, A.A.P.M., de Lima, R.M.T., de Oliveira Filho, J.W.G., Dias, A.C.S., dos Reis, A.C., da Mata, A.M.O.F., MacHado, S.A., Sousa, C.D.D.C., da Silva, F.C.C., Islam, M.T., de Castro E Sousa, J.M., and Melo Cavalcante, A.A.D.C. (2020). Pharmacological effects and toxicogenetic impacts of omeprazole: Genomic instability and cancer. Oxidative Medicine and Cellular Longevity, 2020: 3457890. https://doi.org/10.1155/2020/3457890
- Raza, M., Al-Shabanah, O.A., El-Hadiyah, T.M., and Al-Majed, A.A. (2002). Effect of prolonged vigabatrin treatment on hematological and biochemical parameters in plasma, liver and kidney of Swiss albino mice. Scientia Pharmaceutica, 70: 135-145. https://doi.org/10.3797/scipharm.aut-02-16
- Reimer, C. (2013). Safety of long-term PPI therapy. Best Practice and Research: Clinical Gastroenterology, 27(3): 443-454. DOI: 10.1016/j.bpg.2013.06.001
- Robinson, A.J., Godfrey, A.L. (2021). Low-risk essential thrombocythemia: A comprehensive review. HemaSphere, 5(2): e521. https://doi.org/10.1097/HS9.0000000000000521
- Rosenkranz, H.S., and Klopman, G. (1991). Omeprazole: An exploration of its reported genotoxicity. Mutagenesis, 6(5): 381-384. DOI: 10.1093/mutage/6.5.381
- Savarino, V., di Mario, F., and Scarpignato, C. (2009). Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacological Research, 59(3): 135-153. DOI: 10.1016/j.phrs.2008.09.016
- Scarpignato, C., Gatta, L., Zullo, A., Blandizzi, C. (2016). Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 14: 179. DOI: 10.1186/s12916-016-0718-z
- Skoda, R.C. (2009). Thrombocytosis. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. https://doi.org/10.1182/asheducation-2009.1.159
- Song, J.W., Seo, C.S., Kim, T.I., Moon, O.S., Won, Y.S., Son, H.Y., Son, J.K., and Kwon, H.J. (2016). Protective effects of Manassantin A against ethanol-induced gastric injury in rats. Biological & Pharmaceutical Bulletin, 39(2):221-229. DOI: 10.1248/bpb.b15-00642
- Soon, Y.Y., and Tan, B.K.H. (2002). Evaluation of the hypoglycemic and anti-oxidant activities of Morinda officinalis in streptozotocin-induced diabetic rats. Singapore Medical Journal, 43: 77-85. http://www.smj.org.sg/sites/default/files/4302/4302a4.pdf
- Tan, P.V., Mezui, C., Enow-Orock, G., Njikam, N., Dimo, T., and Bitolog, P. (2008). Teratogenic effects, acute and subchronic toxicity of the leaf aqueous extract of Ocimum suave Wild (Lamiaceae) in rats. Journal of Ethnopharmacology, 115: 232-237. DOI: 10.1016/j.jep.2007.09.022
- Thomson, A.B.R., Sauve, M.D., Kassam, N., and Kamitakahara, H. (2010). Safety of the long-term use of proton pump inhibitors. World Journal of Gastroenterology, 16(19): 2323-2330. DOI: 10.3748/wjg.v16.i19.2323
- Trefts, E., Gannon, M., and Wasserman, D.H. (2017). The liver. Current Biology, 27(21): R1147-R1151. DOI: 10.1016/j.cub.2017.09.019
- United States Food and Drug Administration (2012). Prilosec: Full prescribing information [WWW Document]. US FDA. URL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf (accessed 10.11.21).
- United States Food and Drug Administration (2017). FDA drug safety communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs) [WWW Document]. US FDA. URL https://www.fda.gov/drugs/drugsafety-and-availability/fda-drug-safety-communication-clostridium-difficile-associated-diarrhea-can-be-associated-stomach (accessed 10.10.21).
- Vidya, G., Gladwin, V., and Chand, P. (2015). A comprehensive review on clinical applications of comet assay. Journal of Clinical and Diagnostic Research, 9(3):GE01-GE05. DOI: 10.7860/JCDR/2015/12062.5622
- Voutsadakis, I.A. (2014). Thrombocytosis as a prognostic marker in gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 6(2): 34-40. DOI: 10.4251/wjgo.v6.i2.34
- Weersink, R.A., Bouma, M., Burger, D.M., Drenth, J.P.H., Harkes-Idzinga, S.F., Hunfeld, N.G.M., Metselaar, H.J., Monster-Simons, M.H., van Putten, S.A.W., Taxis, K., and Borgsteede, S.D. (2018). Safe use of proton pump inhibitors in patients with cirrhosis. British Journal of Clinical Pharmacology, 84(8): 1806-1820. DOI: 10.1111/bcp.13615
- Yemitan, O., and Adeyemi, O. (2004). Toxicity studies of the aqueous root extract of Lecaniodiscus cupanioides. Nigerian Journal of Health and Biomedical Sciences, 3(1): 20-23. DOI: 10.4314/njhbs.v3i1.11501
- Zhou, B., Huang, Y., Li, H., Sun, W., and Liu, J. (2016). Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporosis International, 27(1): 339-347. DOI: 10.1007/s00198-015-3365-x